Metaclipse Therapeutics
Phase 1Our proprietary biological adjuvant technology platform involves combining particulate antigen formulations with membrane-linked cytokine and immunostimulatory protein adjuvants. Our biological adjuvants are linked to the antigen source to provide an enhanced immune response and stimulate specific immune pathways to achieve the desired immune response.
Private Company
Funding information not available
About
Our proprietary biological adjuvant technology platform involves combining particulate antigen formulations with membrane-linked cytokine and immunostimulatory protein adjuvants. Our biological adjuvants are linked to the antigen source to provide an enhanced immune response and stimulate specific immune pathways to achieve the desired immune response.